Celsius Holdings, Inc.
$8.04B- Market cap
- $7.76B
- Debt
- +$683.93M
- Cash
- −$398.87M
Capital structure 92% equity / 8% debt · EV / Revenue 3.20x · EV / EBITDA 40.17x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CELH stock price at premium vs ANIP $30.66 current versus $5.36 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANIP's multiple
Implied fair value · at CELH's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CELH FY 2025 (ended Dec 31, 2025) · ANIP FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 92% equity / 8% debt · EV / Revenue 3.20x · EV / EBITDA 40.17x
Capital structure 84% equity / 16% debt · EV / Revenue 1.84x · EV / EBITDA 7.53x
CELH carries the larger enterprise value at $8.04B against $1.63B; ANIP trades on the lower EV / Revenue multiple (1.84x vs 3.20x); ANIP on the lower EV / EBITDA (7.53x vs 40.17x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CELSIUS HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ANI PHARMACEUTICALS, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.58x
0.57x
Net debt / EBITDA
Leverage against operating earnings
1.42x
0.11x
Cash and equivalents
Liquid reserves on the balance sheet
$398.87M
$285.59M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COCA COLA CO
CELH vs KO
PEPSICO INC
CELH vs PEP
Hilton Worldwide Holdings Inc.
CELH vs HLT
Monster Beverage Corp
CELH vs MNST
SUPERNUS PHARMACEUTICALS, INC.
CELH vs SUPN
PERRIGO Co plc
CELH vs PRGO
Viatris Inc
CELH vs VTRS
Organon & Co.
CELH vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
CELH vs TEVA
$683.93M
$309.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.